SAN DIEGO--(BUSINESS WIRE)--
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal third quarter and nine-month period ended April 30, 2018.
Q3: Summary of Results of Operations
Nine Months: Summary of Results of Operations
Hank R. Lambert, CEO, said that, “We’ve experienced a robust start to fiscal Q4 and look forward to ending our year with strong upward momentum. Chipotle reorders for PURE® Hard Surface disinfectant have begun to ramp, normalizing inventory turn. Our core food safety revenues have shown consistent double digit quarterly growth, thereby validating our strategic focus and the game changing nature of our SDC-based solutions. Taylor Farms has expanded use of PURE Control® in two of its produce processing plants – and is executing on its plan for implementation into its 14 plant network. In addition, we continue to generate growing sales of PURE Hard Surface as a truck sanitization solution into the Sysco food transportation network, a new vertical launched earlier this fiscal year.
“Addressing the expense side of the business, we’ve taken steps to significantly reduce our overhead. This combination of revenue momentum and expense control fuels our confidence that we will achieve a cash flow breakeven annual revenue run rate of approximately $7 million in calendar Q1 2019,†concluded Lambert.
2018 Fiscal Third Quarter Financial Results Conference Call
The Participant Dial-In Number for the conference call is 1-631-891-4304. Participants should dial in to the call at least five minutes before 1:30pm PDT (4:30pm ET) on June 13, 2018. The call can also be accessed “live†online at http://public.viavid.com/index.php?id=129853.
A replay of the recorded call will be available for 90 days on the Company’s website (http://www.purebio.com/investors/events-presentations/). You can also listen to a replay of the call by dialing 1-844-512-2921 (international participants dial 1-412-317-6671) starting June 13, 2018, at 7:30pm ET through June 20, 2018 at 11:59pm ET. Please use PIN Number 10004941.
About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena -- providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and it mitigates bacterial resistance. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
Forward-looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company's current and future products and services in the marketplace, including the Company’s ability to convert successful evaluations and tests for PURE Control into customer orders and customers continuing to place product orders as expected and to expand their use of the Company’s products; the Company’s ability to raise the funding required to support its continued operations and the implementation of its business plan; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw meat processing and to expand its use in OLR poultry processing; competitive factors, including customer acceptance of the Company’s SDC-based products that are typically more expensive than existing treatment chemicals; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2017 and Form 10-Q for the third fiscal quarter ended April 30, 2018. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
| PURE Bioscience, Inc. | ||||||||
| Condensed Consolidated Balance Sheets | ||||||||
| April 30, 2018 | July 31, 2017 | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 1,018,000 | $ | 1,640,000 | ||||
| Accounts receivable | 192,000 | 297,000 | ||||||
| Inventories, net | 275,000 | 273,000 | ||||||
| Restricted cash | 75,000 | 75,000 | ||||||
| Prepaid expenses | 52,000 | 174,000 | ||||||
| Total current assets | 1,612,000 | 2,459,000 | ||||||
| Property, plant and equipment, net | 487,000 | 548,000 | ||||||
| Patents, net | 701,000 | 822,000 | ||||||
| Total assets | $ | 2,800,000 | $ | 3,829,000 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 486,000 | $ | 426,000 | ||||
| Accrued liabilities | 137,000 | 249,000 | ||||||
| Derivative liabilities | — | 1,853,000 | ||||||
| Total current liabilities | 623,000 | 2,528,000 | ||||||
| Deferred rent | 15,000 | 11,000 | ||||||
| Total liabilities | 638,000 | 2,539,000 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity | ||||||||
| Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding | — | — | ||||||
| Common stock, $0.01 par value: 100,000,000 shares authorized, 68,076,408 shares issued and outstanding at April 30, 2018, and 63,093,153 shares issued and outstanding at July 31, 2017 | 681,000 | 631,000 | ||||||
| Additional paid-in capital | 117,021,000 | 110,141,000 | ||||||
| Accumulated deficit | (115,540,000 | ) | (109,482,000 | ) | ||||
| Total stockholders’ equity | 2,162,000 | 1,290,000 | ||||||
| Total liabilities and stockholders’ equity | $ | 2,800,000 | $ | 3,829,000 | ||||
| PURE Bioscience, Inc. | ||||||||||||||||
| Condensed Consolidated Statements of Operations | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Nine Months Ended |
Three Months Ended |
|||||||||||||||
| April 30, | April 30, | |||||||||||||||
| 2018 | 2017 | 2018 | 2017 | |||||||||||||
| Net product sales | $ | 1,265,000 | $ | 1,316,000 | $ | 390,000 | $ | 338,000 | ||||||||
| Operating costs and expenses | ||||||||||||||||
| Cost of goods sold | 473,000 | 531,000 | 166,000 | 132,000 | ||||||||||||
| Selling, general and administrative | 4,102,000 | 3,972,000 | 1,239,000 | 1,302,000 | ||||||||||||
| Research and development | 381,000 | 684,000 | 117,000 | 222,000 | ||||||||||||
| Share-based compensation | 1,975,000 | 723,000 | 579,000 | 275,000 | ||||||||||||
| Total operating costs and expenses | 6,931,000 | 5,910,000 | 2,101,000 | 1,931,000 | ||||||||||||
| Loss from operations | (5,666,000 | ) | (4,594,000 | ) | (1,711,000 | ) | (1,593,000 | ) | ||||||||
| Other income (expense) | ||||||||||||||||
| Inducement to exercise warrants | (876,000 | ) | — | — | — | |||||||||||
| Change in derivative liabilities | 459,000 | 153,000 | — | (147,000 | ) | |||||||||||
| Interest expense, net | (3,000 | ) | (4,000 | ) | (1,000 | ) | (1,000 | ) | ||||||||
| Other income, net | 28,000 | 28,000 | 20,000 | 3,000 | ||||||||||||
| Total other income (expense) | (392,000 | ) | 177,000 | 19,000 | (145,000 | ) | ||||||||||
| Net loss | $ | (6,058,000 | ) | $ | (4,417,000 | ) | $ | (1,692,000 | ) | $ | (1,738,000 | ) | ||||
| Basic and diluted net loss per share | $ | (0.09 | ) | $ | (0.07 | ) | $ | (0.02 | ) | $ | (0.03 | ) | ||||
| Shares used in computing basic and diluted net loss per share | 66,996,085 | 63,718,152 | 68,057,658 | 62,679,644 | ||||||||||||
| PURE Bioscience, Inc. | ||||||||
| Condensed Consolidated Statements of Cash Flows | ||||||||
| (Unaudited) | ||||||||
| Nine Months Ended | ||||||||
| April 30, | ||||||||
| 2018 | 2017 | |||||||
| Operating activities | ||||||||
| Net loss | $ | (6,058,000 | ) | $ | (4,417,000 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Share-based compensation | 1,975,000 | 723,000 | ||||||
| Amortization of stock issued for services | 115,000 | 108,000 | ||||||
| Depreciation and amortization | 213,000 | 204,000 | ||||||
| Gain on inventory recovery | (19,000 | ) | — | |||||
| Change in fair value of derivative liabilities | (459,000 | ) | (153,000 | ) | ||||
| Inducement to exercise warrants | 876,000 | — | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | 105,000 | 78,000 | ||||||
| Inventories | 17,000 | 2,000 | ||||||
| Prepaid expenses | 60,000 | (5,000 | ) | |||||
| Accounts payable and accrued liabilities | (52,000 | ) | 58,000 | |||||
| Deferred rent | 4,000 | 9,000 | ||||||
| Net cash used in operating activities | (3,223,000 | ) | (3,393,000 | ) | ||||
| Investing activities | ||||||||
| Investment in patents | (12,000 | ) | (11,000 | ) | ||||
| Purchases of property, plant and equipment | (19,000 | ) | (205,000 | ) | ||||
| Net cash used in investing activities | (31,000 | ) | (216,000 | ) | ||||
| Financing activities | ||||||||
| Net proceeds from the exercise of warrants | 2,632,000 | 80,000 | ||||||
| Net proceeds from the sale of common stock | — | 1,049,000 | ||||||
| Net cash provided by financing activities | 2,632,000 | 1,129,000 | ||||||
| Net decrease in cash and cash equivalents | (622,000 | ) | (2,480,000 | ) | ||||
| Cash and cash equivalents at beginning of period | 1,640,000 | 5,194,000 | ||||||
| Cash and cash equivalents at end of period | $ | 1,018,000 | $ | 2,714,000 | ||||
| Supplemental disclosure of cash flow information | ||||||||
| Cash paid for taxes | $ | — | $ | 2,000 | ||||
| Noncash Investing and Financing activities | ||||||||
| Warrant liabilities removed due to settlements | $ | 1,394,000 | $ | 8,000 | ||||
| Common stock issued for prepaid services | $ | 51,000 | $ | — | ||||
| Restricted stock unit cancelation | $ | — | $ | 38,000 | ||||